黄金城游戏

The 5^th NEXTGEN CHINA 2015

-- ag凯发k8真人娱乐

Organized by: CPhI Conferences & UBM

Website: http://www.nextgen-china.com/

March 25-27, 2014

Shanghai China

7 Compelling Reasons to Attend

*Delving into key trends of generics regulatory, market and technology

*Impurity research and & QbD implementation case study

*Hearing in-depth presentations from 20+ global speakers under CPhI resources

*Covering 2 Chapters: Regulation compliance and GENERICS CONSISTENCY EVALUATION and market strategy analysis along with the technology updating

*Networking with and 150+ decision makers from pharmaceutical companies

*Benefiting from case studies from leading generic pharmacy of US, EU and India

*15+ professional presentations, 2 workshops and 2+ panel discussion, getting on-spot answers to your critical business and technical challenges

Conference Background:

The global generics market size reached $170 billion in 2013. In the past 10 years, the market development growth of generics was twice as much as innovator drugs. In the next few years, there will be a drug patents expire peak. 1295 generic drugs will be off-patent during the year 2014 to 2018, which will affect $19.7 billion in total. – Data from Analysis report on production and marketing of chemical pharmaceutical industry in China during 2015-2020.

There are lot of opportunities for Chinese generics industry development. However, how to manufacture international high quality generics is still a key issue for manufacturers.

*How to understand GENERICS CONSISTENCY EVALUATION and how to make product meet the requirement of regulation?

*Stricter of regulation from FDA&EU, how to access to overseas market?

*How to do impurity control and dissolution rate comparison?

*How implement QbD successfully and how to do cost reduction strategies?

*How to improve equivalence to increase generics quality and drug internationalization

*Diversified development of generics market, M&A of pharmacy, strategic cooperation, generics branding, supergenerics, biosimilars and influence of CRO & CMO…

The 5^th NEXTGEN CHINA 2015 will gather all resource of CPhI global and essence of past four 黄金城游戏s to explore topics above and showcase evolving generics landscape & solutions.

Conference Structure:

Pre-Conference Workshop (March 25, 2015)

Morning: How to do generics impurity research scientifically and reasonably combing with registration requirement

Afternoon: Application and case analysis of Quality by Design (QbD) in generics R&D and manufacture

Day One (March 26, 2015)

Regulation compliance and Generics Consistency Evaluation

Day Two (March 27, 2015)

Market strategy analysis of generics along with the techniques updates

Past Attendees of NEXTGEN:

Teva, Mylan, Sandoz, Pfizer, GSK, Boehringer-Ingelheim, AstraZeneca, Sanofi, Movartis, Merck, JNJ, Abbott, Bristol-Myers Squibb, Bayer, Roche, Dr. Reddy’s, Shanghai Pharma Group, Huhai, Hengrui, Yangtze River, Tasly, China Resources, Xian-Janssen, Qilu, Zhejiang Medicine, Wuhan Humanwell, Northeast Pharm, North China Pharmaceutical, Sinopharm, Kelun Group…

Who Should Attend?

Job Title

(Pie Chart)

Decision Makers 25%

R&D 25%

Regulatory Affairs 10%

Marketing 10%

BD 10%

QA/QC 10%

Manufacture 5%

Others 5%

Industry Sectors

(Pie Chart)

Government/Regulatory/Association/Research 10%

Generics/Biosimilar Manufacturers 50%

Innovator Pharma Manufacturers 10%

CRO&CMO 10%

API, Ingredient & Material Suppliers 5%

Equipment/Service/IT/PAT Suppliers 5%

Finance/Investment/VC 5%

Marketing/Consulting/Others 5%

Tel: 86-21-61573868/61573922

Email: ask黄金城游戏@ubm.com